Mind Medicine (MindMed) Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Mind Medicine (MindMed) Inc 公司

Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Mind Medicine (MindMed) Inc简介



公司代码MNMD

公司名称Mind Medicine (MindMed) Inc

上市日期May 04, 2015

CEOBarrow (Robert B)

员工数量74

证券类型Ordinary Share

年结日May 04

公司地址One World Trade Center

城市NEW YORK

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编10007

电话12122206633

网址https://ir.mindmed.co/

公司代码MNMD

上市日期May 04, 2015

CEOBarrow (Robert B)

Mind Medicine (MindMed) Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Robert (Rob) Barrow

Chief Executive Officer, Director

518.46K

+320000.00%

Mr. Mark R. Sullivan

Chief Legal Officer, Corporate Secretary

20.08K

-11276.00%

Dr. Suzanne Louise (Sue) Bruhn, Ph.D.

Independent Director

17.64K

+5402.00%

Dr. Roger Crystal, M.D.

Independent Director

17.64K

+5402.00%

Mr. David W. (Dave) Gryska

Independent Director

10.62K

-9234.00%

Dr. Daniel R. Karlin, M.D.

Chief Medical Officer

--

Mr. Andreas R. Krebs

Independent Vice Chairman of the Board

--

Ms. Carol A. Vallone

Independent Chairman of the Board

--

Mr. Matthew T. Wiley

Chief Commercial Officer

--

Mr. Chris Brinzey

IR Contact Officer

--

名称

名称/职务

职务

持股

持股变动

Mr. Robert (Rob) Barrow

Chief Executive Officer, Director

518.46K

+320000.00%

Mr. Mark R. Sullivan

Chief Legal Officer, Corporate Secretary

20.08K

-11276.00%

Dr. Suzanne Louise (Sue) Bruhn, Ph.D.

Independent Director

17.64K

+5402.00%

Dr. Roger Crystal, M.D.

Independent Director

17.64K

+5402.00%

Mr. David W. (Dave) Gryska

Independent Director

10.62K

-9234.00%

Dr. Daniel R. Karlin, M.D.

Chief Medical Officer

--

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 2月7日周六

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

5.34%

Commodore Capital LP

3.27%

Driehaus Capital Management, LLC

3.16%

Blackstone Alternative Asset Management, L.P.

2.82%

The Vanguard Group, Inc.

2.61%

其他

82.80%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

5.34%

Commodore Capital LP

3.27%

Driehaus Capital Management, LLC

3.16%

Blackstone Alternative Asset Management, L.P.

2.82%

The Vanguard Group, Inc.

2.61%

其他

82.80%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

16.81%

Investment Advisor

13.43%

Hedge Fund

11.26%

Research Firm

1.58%

Individual Investor

1.28%

Private Equity

0.37%

Bank and Trust

0.33%

Pension Fund

0.13%

Venture Capital

0.10%

其他

54.71%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

418

43.37M

44.02%

-6.65M

2025Q3

385

42.65M

43.29%

-5.82M

2025Q2

380

42.59M

55.97%

-6.05M

2025Q1

383

42.99M

56.91%

-5.37M

2024Q4

358

42.80M

58.58%

-14.39M

2024Q3

346

50.91M

62.84%

+1.65M

2024Q2

371

44.11M

63.15%

+4.97M

2024Q1

368

37.27M

54.54%

+28.87M

2023Q4

362

7.25M

18.10%

-366.43K

2023Q3

378

6.32M

16.16%

-494.13K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

5.26M

5.34%

+38.15K

+0.73%

Sep 30, 2025

Commodore Capital LP

3.23M

3.27%

-1.77M

-35.50%

Sep 30, 2025

Driehaus Capital Management, LLC

3.11M

3.16%

+17.25K

+0.56%

Sep 30, 2025

Blackstone Alternative Asset Management, L.P.

2.78M

2.82%

-810.92K

-22.60%

Sep 30, 2025

The Vanguard Group, Inc.

2.00M

2.03%

+198.88K

+11.04%

Sep 30, 2025

Marshall Wace LLP

2.38M

2.42%

-1.04M

-30.38%

Sep 30, 2025

Octagon Capital Advisors LP

2.13M

2.16%

--

Sep 30, 2025

State Street Investment Management (US)

1.92M

1.95%

+119.00K

+6.59%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.82M

1.85%

+91.25K

+5.26%

Sep 30, 2025

Deep Track Capital LP

1.50M

1.52%

-1.00M

-40.00%

Sep 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

AdvisorShares Psychedelics ETF

9.95%

State Street SPDR S&P Pharmaceuticals ETF

2.17%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.54%

Virtus LifeSci Biotech Clinical Trials ETF

1.32%

iShares U.S. Pharmaceuticals ETF

0.4%

iShares Micro-Cap ETF

0.21%

ProShares Ultra Nasdaq Biotechnology

0.11%

Invesco Nasdaq Biotechnology ETF

0.11%

Nuveen ESG Small-Cap ETF

0.08%

iShares ESG Aware MSCI USA Small-Cap ETF

0.07%

AdvisorShares Psychedelics ETF

占比9.95%

State Street SPDR S&P Pharmaceuticals ETF

占比2.17%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.54%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.32%

iShares U.S. Pharmaceuticals ETF

占比0.4%

iShares Micro-Cap ETF

占比0.21%

ProShares Ultra Nasdaq Biotechnology

占比0.11%

Invesco Nasdaq Biotechnology ETF

占比0.11%

Nuveen ESG Small-Cap ETF

占比0.08%

iShares ESG Aware MSCI USA Small-Cap ETF

占比0.07%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

公告日期

除权除息日

类型

比率

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1